Reading tumor biology in liquid
Cancer behavior is written in gene expression. The genes a tumor turns on and off define its lineage, its active pathways, and the targets it presents to therapy. Simply put, it’s biology that DNA alterations alone cannot fully resolve.
Our ExpressCT™ technology reads cell-free DNA fragmentation patterns to measure gene expression from a tube of blood – no tissue or separate RNA assay needed.
A gene expression readout delivered from cfDNA becomes a biomarker. From molecular subtype to pathway activation to target expression, we translate it into signatures that identify the patients most likely to respond, and we track how that biology shifts over time.
ExpressCT™: separating signal from noise
Most ctDNA fragmentation data is noise. Direct one-to-one transfer of tissue expression signatures to blood is unreliable and overwhelmed by background.
We relied on years of experience and a pipeline of RNA-based tissue gene expression signatures to approach the challenge of translating tissue signatures into blood-based versions.
Using advanced, proprietary machine learning, ExpressCT™ sifts through blood gene expression features to eliminate noise and identify an enriched population of highly concordant ctDNA features that accurately reflect tumor gene expression – the expression-relevant ctDNA fragmentome.
The expression-relevant ctDNA fragmentome can be used to create blood versions of any tumor RNA-based expression signature or develop entirely new expression signatures from cfDNA alone.
